RU94046278A - METHODS AND PREPARATIONS FOR TREATMENT OF DISEASES BY INTERFERON CHARACTERIZED BY REDUCED SIDE EFFECTS - Google Patents

METHODS AND PREPARATIONS FOR TREATMENT OF DISEASES BY INTERFERON CHARACTERIZED BY REDUCED SIDE EFFECTS

Info

Publication number
RU94046278A
RU94046278A RU94046278/14A RU94046278A RU94046278A RU 94046278 A RU94046278 A RU 94046278A RU 94046278/14 A RU94046278/14 A RU 94046278/14A RU 94046278 A RU94046278 A RU 94046278A RU 94046278 A RU94046278 A RU 94046278A
Authority
RU
Russia
Prior art keywords
coordinated
human leukocyte
interferon
therapeutically effective
leukocyte interferon
Prior art date
Application number
RU94046278/14A
Other languages
Russian (ru)
Other versions
RU2128056C1 (en
Inventor
Лоуренс М. Блатт
Милтон У. Тейлор
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/868,916 external-priority patent/US5372808A/en
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of RU94046278A publication Critical patent/RU94046278A/en
Application granted granted Critical
Publication of RU2128056C1 publication Critical patent/RU2128056C1/en

Links

Claims (25)

1. Способ лечения пациентов, страдающих состояниями, поддающимися лечению интерфероном, характеризующийся сниженными или устраненными одним или более побочными эффектами, сопутствующими лечению интерфероном, и включающий назначение таким пациентам терапевтически эффективных количеств "согласованного" (consensus) человеческого лейкоцитарного интерферона.1. A method of treating patients suffering from conditions treatable with interferon, characterized by reduced or eliminated one or more side effects concomitant with treatment with interferon, and comprising administering to such patients therapeutically effective amounts of “consensus” human leukocyte interferon. 2. Способ по п. 1, характеризующийся тем, что упомянутыми состояниями являются расстройства клеточной пролиферации или вирусные заболевания. 2. The method according to p. 1, characterized in that the said conditions are disorders of cell proliferation or viral diseases. 3. Способ по п. 2, характеризующийся тем, что упомянутыми вирусными заболеваниями являются гепатит А, гепатит В, гепатит С или гепатит дельта. 3. The method according to p. 2, characterized in that the said viral diseases are hepatitis A, hepatitis B, hepatitis C or hepatitis delta. 4. Способ по п. 2, характеризующийся тем, что упомянутыми вирусными заболеваниями являются вирусные заболевания, которые выбраны из группы, включающей папилому и заболевания, вызванные вирусом иммунодефицита человека, вирусом простого герпеса, поксвирусом, пикорновирусом, аденовирусом, пиновирусом, вирусом HTLV I, вирусом HTLV II и ротавирусом человека. 4. The method according to p. 2, characterized in that the said viral diseases are viral diseases that are selected from the group comprising papilloma and diseases caused by human immunodeficiency virus, herpes simplex virus, poxvirus, picornovirus, adenovirus, pinovirus, HTLV I virus, HTLV II virus and human rotavirus. 5. Способ по п. 1, характеризующийся тем, что упомянутый побочный эффект является побочным эффектом, выбранным из группы, включающей головную боль, лихорадку, озноб, тошноту, потерю аппетита, депрессию и бессоницу. 5. The method according to p. 1, characterized in that said side effect is a side effect selected from the group including headache, fever, chills, nausea, loss of appetite, depression and insomnia. 6. Способ по п. 2, характеризующийся тем, что упомянутыми расстройствами клеточной пролиферации являются волосистая клеточная лейкемия или хроническая миелогенная лейкемия. 6. The method according to p. 2, characterized in that the said disorders of cell proliferation are fibrous cell leukemia or chronic myelogenous leukemia. 7. Способ по п. 2, характеризующийся тем, что упомянутым расстройством клеточной пролиферации является саркома Капоши. 7. The method according to p. 2, characterized in that the said disorder of cell proliferation is Kaposi's sarcoma. 8. Способ по п. 1, характеризующийся тем, что "согласованный" человеческий лейкоцитарный интерферон является "согласованным" интерфероном, выбранным из группы, включающей IFN-con1, IFN-con2 и IFN-соn3. 8. The method according to p. 1, characterized in that the "coordinated" human leukocyte interferon is a "coordinated" interferon selected from the group comprising IFN-con1, IFN-con2 and IFN-con3. 9. Способ по п. 1, характеризующийся тем, что "согласованный" человеческий лейкоцитарный интерферон является IFN-con1. 9. The method according to p. 1, characterized in that the "coordinated" human leukocyte interferon is IFN-con1. 10. Способ по п. 1, характеризующийся тем, что "согласованный" человеческий лейкоцитарный интерферон является продуктом экспрессии экзогенной последовательности ДНК прокариотов. 10. The method according to p. 1, characterized in that the "coordinated" human leukocyte interferon is an expression product of the exogenous DNA sequence of prokaryotes. 11. Способ по п. 1, характеризующийся тем, что терапевтически эффективное количество препарата назначают перорально, внутривенно, внутримышечно, подкожно, интраназально или в место поражения. 11. The method according to p. 1, characterized in that the therapeutically effective amount of the drug is administered orally, intravenously, intramuscularly, subcutaneously, intranasally or at the site of the lesion. 12. Способ по п. 1, характеризующийся тем, что терапевтически эффективное количество "согласованного" человеческого лейкоцитарного интерферона составляет от 2•106 до 30•106 единиц на пациента.12. The method according to p. 1, characterized in that the therapeutically effective amount of a "coordinated" human leukocyte interferon is from 2 • 10 6 to 30 • 10 6 units per patient. 13. Способ по п. 1, характеризующийся тем, что терапевтически эффективное количество "согласованного" человеческого лейкоцитарного интерферона составляет от 6•106 до 15•106 единиц на пациента.13. The method according to p. 1, characterized in that the therapeutically effective amount of a "coordinated" human leukocyte interferon is from 6 • 10 6 to 15 • 10 6 units per patient. 14. Способ по п. 1, характеризующийся тем, что пациентом является человек. 14. The method according to p. 1, characterized in that the patient is a person. 15. Способ по п. 1, характеризующийся тем, что дополнительно включает назначение терапевтически эффективного количества химиотерапевтического агента. 15. The method according to p. 1, characterized in that it further includes the appointment of a therapeutically effective amount of a chemotherapeutic agent. 16. Способ по п. 1, характеризующийся тем, что дополнительно включает назначение терапевтически эффективного количества стимулирующего колонии гранулоцитов фактора. 16. The method according to p. 1, characterized in that it further includes the appointment of a therapeutically effective amount of a stimulating colony of granulocyte factor. 17. Препарат, включающий терапевтически эффективное количество "согласованного" человеческого лейкоцитарного интерферона и фармацевтически приемлемый разбавитель, вспомогательное вещество, носитель, консервант или солюбилизатор. 17. A preparation comprising a therapeutically effective amount of a “coordinated” human leukocyte interferon and a pharmaceutically acceptable diluent, excipient, carrier, preservative or solubilizer. 18. Препарат по п. 17, характеризующийся тем, что "согласованным" человеческим лейкоцитарным интерфероном является "согласованный" человеческий лейкоцитарный интерферон, выбранный из группы, включающей IFN-con1, IFN-con2 или IFN-соn3. 18. The drug according to p. 17, characterized in that the "coordinated" human leukocyte interferon is a "coordinated" human leukocyte interferon selected from the group comprising IFN-con1, IFN-con2 or IFN-con3. 19. Препарат по п. 17, характеризующийся тем, что "согласованным" человеческим лейкоцитарным интерфероном является IFN-con1. 19. The drug according to p. 17, characterized in that the "coordinated" human leukocyte interferon is IFN-con1. 20. Препарат по п. 17, характеризующийся тем, что "согласованный" человеческий лейкоцитарный интерферон является продуктом экспрессии экзогенной последовательности ДНК прокариотов. 20. The drug according to p. 17, characterized in that the "coordinated" human leukocyte interferon is a product of the expression of the exogenous DNA sequence of prokaryotes. 21. Препарат по п. 17, характеризующийся тем, что является пригодным для назначения перорально, внутривенно, внутримышечно, подкожно, интраназально или в место поражения. 21. The drug according to p. 17, characterized in that it is suitable for administration orally, intravenously, intramuscularly, subcutaneously, intranasally or at the site of the lesion. 22. Препарат по п. 17, характеризующийся тем, что представляет собою инъекционный раствор. 22. The drug according to p. 17, characterized in that it is an injection solution. 23. Препарат по п. 17, характеризующийся тем, что дополнительно включает терапевтически эффективное количество стимулирующего колонии гранулоцитов фактора. 23. The drug according to p. 17, characterized in that it further includes a therapeutically effective amount of a stimulating colony of granulocyte factor. 24. Способ лечения вирусных заболеваний интерфероном без достижения одной или большего числа доз, ограничиваемых токсичностью, характеризующийся тем, что при такой необходимости пациенту назначают терапевтически эффективное количество "согласованного" человеческого лейкоцитарного интерферона. 24. A method of treating viral diseases with interferon without achieving one or more doses limited by toxicity, characterized in that, if necessary, the patient is prescribed a therapeutically effective amount of “coordinated” human leukocyte interferon. 25. Способ лечения расстройств клеточной пролиферации или вирусных заболеваний, не вызывающий значительных побочных эффектов, обычно сопутствующих терапии интерфероном, включающий назначение пациенту терапевтически эффективного количества "согласованного" человеческого лейкоцитарного интерферона. 25. A method of treating cell proliferation disorders or viral diseases that does not cause significant side effects, usually associated with interferon therapy, comprising administering to the patient a therapeutically effective amount of “coordinated” human leukocyte interferon.
RU94046278A 1992-04-15 1993-04-14 Methods and preparations for treatment of patients with interferon exhibiting decreased adverse effects RU2128056C1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/868,916 1992-04-15
US07/868,916 US5372808A (en) 1990-10-17 1992-04-15 Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US07/868.916 1992-04-15
PCT/US1993/004471 WO1993021229A1 (en) 1992-04-15 1993-04-14 Methods and compositions for the treatment of diseases with interferon while reducing side effects

Publications (2)

Publication Number Publication Date
RU94046278A true RU94046278A (en) 1998-02-10
RU2128056C1 RU2128056C1 (en) 1999-03-27

Family

ID=25352556

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94046278A RU2128056C1 (en) 1992-04-15 1993-04-14 Methods and preparations for treatment of patients with interferon exhibiting decreased adverse effects

Country Status (27)

Country Link
US (1) US5372808A (en)
EP (3) EP0911033B2 (en)
JP (2) JPH07505894A (en)
KR (1) KR950701350A (en)
CN (1) CN1098103C (en)
AT (1) ATE254926T1 (en)
AU (1) AU683214B2 (en)
CA (1) CA2118121C (en)
CZ (1) CZ247194A3 (en)
DE (1) DE69333321T3 (en)
DK (1) DK0911033T4 (en)
ES (1) ES2210864T5 (en)
HK (1) HK1018595A1 (en)
HU (1) HU227310B1 (en)
IL (1) IL105366A (en)
MX (1) MX9302160A (en)
NO (1) NO318643B1 (en)
NZ (1) NZ252871A (en)
PT (1) PT911033E (en)
RO (1) RO115700B1 (en)
RU (1) RU2128056C1 (en)
SG (1) SG52443A1 (en)
SK (1) SK284712B6 (en)
TW (1) TW265265B (en)
UA (1) UA44223C2 (en)
WO (1) WO1993021229A1 (en)
ZA (1) ZA932641B (en)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
WO1993016107A1 (en) * 1992-02-10 1993-08-19 Interferon Sciences, Inc. Improved alpha interferon composition and method for its production from human peripheral blood leukocytes
JPH09501827A (en) * 1993-06-11 1997-02-25 ペストカ バイオメディカル ラボラトリーズ インコーポレイテッド Superproteins including interferons and interleukins
US6001589A (en) * 1993-06-11 1999-12-14 Pbl Biomedical Laboratories, Inc. Method of identifying proteins modified by disease states related thereto
WO1995015177A2 (en) * 1993-12-02 1995-06-08 President And Fellows Of Harvard College Improved efficacy of alpha-helical cytokines
DE69521880T2 (en) * 1994-02-08 2002-01-03 Amgen Inc ORAL ADMINISTRATION SYSTEM OF CHEMICALLY MODIFIED PROTEINS G-CSF
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL116730A0 (en) * 1995-01-13 1996-05-14 Amgen Inc Chemically modified interferon
EP0790062B1 (en) * 1995-08-30 2006-05-10 Toray Industries, Inc. Method of testing for myocarditis and cariomyopathy
ATE262920T1 (en) 1995-11-02 2004-04-15 Schering Corp CONTINUOUS, LOW DOSE CYTOKINE INFUSION THERAPY
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US20030026779A1 (en) * 1999-10-15 2003-02-06 Liming Yu Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
US5831062A (en) * 1996-05-09 1998-11-03 Amgen Inc. Use of the human interferon consensus gene for gene therapy
JP3806445B2 (en) * 1996-05-09 2006-08-09 ファーマ・パシフィック・プロプライエタリー・リミテッド Method of treatment
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6432398B1 (en) * 1998-09-29 2002-08-13 W. Robert Fleischmann Methods of treating diseased cells
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
RU2140285C1 (en) 1999-01-25 1999-10-27 Гапонюк Петр Яковлевич Antiviral agent - nasal drops "grippferon"
HU228488B1 (en) * 1999-01-29 2013-03-28 Amgen Inc Gcsf conjugates
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN1315862C (en) 2000-05-26 2007-05-16 艾登尼科斯（开曼）有限公司 Methods and compositions for treating flaviviruses and pestiviruses
US7105154B2 (en) * 2000-07-19 2006-09-12 Pepgen Corporation Method of treatment using interferon-tau
AU2002243438A1 (en) 2000-10-25 2002-07-24 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
AU2002227252A1 (en) * 2000-12-01 2002-06-11 Cornell Research Foundation Animal model for flaviviridae infection
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
US20050079579A1 (en) * 2001-02-28 2005-04-14 Guangwen Wei Uses of spatial configuration to modulate protein function
CN1245215C (en) * 2001-02-28 2006-03-15 四川省生物工程研究中心 Recombination high efficiency composite interferon used as hepatitis B surface antigen and e antigen inhibitor
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20050031585A1 (en) * 2001-09-28 2005-02-10 Hsu Henry H. Method for treating hepatitis c virus infection in treatment failure patients
PL369129A1 (en) * 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
JP2005508332A (en) * 2001-09-28 2005-03-31 メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ Co-administration of transport protein and conjugated cobalamin for drug delivery
JP2005504087A (en) * 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド Methods and compositions for the treatment of hepatitis C virus using 4 'modified nucleosides
MXPA04003238A (en) * 2001-10-05 2004-07-08 Intermune Inc Method of treating hepatitis virus infection with a multiphasic interferon delivery profile.
JP2005517648A (en) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド Compositions and methods for treating hepatitis virus infections
JP2006501137A (en) * 2002-01-16 2006-01-12 ペプジェン コーポレイション Oral administration of interferon-τ
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CN1678326A (en) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
TW200500374A (en) 2002-06-28 2005-01-01 Idenlx Cayman Ltd 2' and 3' -nucleoside produrgs for treating flavivridae infections
GB0215293D0 (en) * 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
CA2506129C (en) 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
EP2319853B1 (en) 2002-12-12 2014-03-12 IDENIX Pharmaceuticals, Inc. Process for the production of 2'-branched nucleosides
US20070072181A1 (en) * 2003-02-28 2007-03-29 Blatt Lawrence M Combination therapy for treating alphavirus infection and liver fibrosis
WO2004078127A2 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Continuous delivery methods for treating hepatitis virus infection
SI2604620T1 (en) 2003-05-30 2016-10-28 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Modified fluorinated nucleoside analogues
ES2351603T3 (en) * 2003-07-25 2011-02-08 Idenix Pharmaceuticals, Inc. PURINE NUCLEOSID ANALOGS FOR THE TREATMENT OF DISEASES CAUSED BY FLAVIRIDAE INCLUDING HEPATITIS C.
EP1663110B1 (en) 2003-08-28 2013-12-18 Superlab Far East Limited Uses of interferons with altered spatial structure
ES2528218T3 (en) * 2003-08-28 2015-02-05 Superlab Far East Limited Uses of interferons with modified spatial structure
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
MXPA06003963A (en) 2003-10-14 2006-08-25 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication.
WO2005063744A2 (en) * 2003-12-22 2005-07-14 K.U. Leuven Research & Development IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT
EP1711159B1 (en) 2003-12-30 2013-03-20 Durect Corporation Solid implants containing a block copolymer for controlled release of a gnrh compound
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
US7318918B2 (en) 2004-05-19 2008-01-15 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
CN101023094B (en) 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
EP3109244B1 (en) 2004-09-14 2019-03-06 Gilead Pharmasset LLC Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
EP2749290A3 (en) 2005-03-09 2015-02-18 Guangwen Wei Uses of recombinant super-compound interferons
JP4516863B2 (en) * 2005-03-11 2010-08-04 株式会社ケンウッド Speech synthesis apparatus, speech synthesis method and program
US7619067B2 (en) 2005-05-18 2009-11-17 Maxygen, Inc. Evolved interferon-alpha polypeptides
MX2008001166A (en) 2005-07-25 2008-03-18 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication.
ES2356776T3 (en) 2005-10-11 2011-04-13 Intermune, Inc. COMPOUNDS AND METHODS TO INHIBIT THE REPLICATION OF THE HEPATITIS VIRUS.
CA2634749C (en) 2005-12-23 2014-08-19 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
CA2648077A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101525381B (en) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 Novel recombinant consensus interferon and construction of a high-efficiency expression vector thereof
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
KR20110104074A (en) 2008-12-23 2011-09-21 파마셋 인코포레이티드 Synthesis of purine nucleosides
EP2376088B1 (en) * 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
AU2009329917B2 (en) * 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (en) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
BRPI1012951A2 (en) * 2009-06-09 2016-07-26 Defyrus Inc "administration of interferon for prophylaxis or treatment of pathogen infection"
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
CN102101886A (en) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 Variable-conformation recombinant interferon crystal, and three-dimensional structure and use thereof
HUE034239T2 (en) 2010-03-31 2018-02-28 Gilead Pharmasset Llc Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
US20120123338A1 (en) 2010-06-16 2012-05-17 Medtronic, Inc. Damping systems for stabilizing medications in drug delivery devices
CA3138758A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Highly soluble leptins
TW201242974A (en) 2010-11-30 2012-11-01 Gilead Pharmasset Llc Compounds
BRPI1107312B1 (en) * 2011-11-25 2021-09-08 Universidade Federal De Santa Catarina ACYL HYDRAZONE COMPOUND
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
TWI726291B (en) * 2013-01-07 2021-05-01 英屬維爾京群島商遠東超級實驗室有限公司 Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
PT3038601T (en) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES506955A0 (en) † 1980-11-10 1983-02-01 Genentech Inc A PROCEDURE FOR PRODUCING AN ANTI-VIRAL POLYPEPTIDE.
US6936694B1 (en) † 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
SE8502430L (en) † 1985-05-15 1986-11-16 Kabivitrum Ab A CDNA MOLECULE CODING FOR THE EXPRESSION OF A POLYPEPTIDE OF THE INTERFERON ALFA TYPE, A BACTERIAL OR CELLULAR WORTH TRANSFORMED WITH SUCH A MOLECULE AND A POLYPEPTIDE SHOWING THE INTERFERON ACTIVITY MADE
EP0205404B1 (en) † 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
CA2094275C (en) * 1990-10-17 2003-06-03 Lawrence M. Blatt Methods and compositions for the treatment of cell proliferation disorders

Similar Documents

Publication Publication Date Title
RU94046278A (en) METHODS AND PREPARATIONS FOR TREATMENT OF DISEASES BY INTERFERON CHARACTERIZED BY REDUCED SIDE EFFECTS
CA2253490C (en) Use of il-12 and ifn-.alpha. for the treatment of infectious diseases
EP0741577B1 (en) The use of interferon subtype alpha 8 in the preparation of medicaments to treat viral infections of the liver
RU95113492A (en) THERAPEUTIC COMBINATION CONTAINING THE HUMAN INTERFERON, ITS APPLICATION, PHARMACEUTICAL DRUG, PACKAGING AND METHOD OF TREATMENT
CA2118121A1 (en) Methods and compositions for the treatment of diseases with interferon while reducing side effects
CA2236591A1 (en) Continuous low-dose cytokine infusion therapy
CA2105165A1 (en) Dosage form for a delayed drug-delivery
CA1296252C (en) Method and composition for prophylaxis and treatment of viral infections
Stadler et al. Long-term combined rIFN-alpha-2a and zidovudine therapy for HIV-associated Kaposi's sarcoma: clinical consequences and side effects
EP0462305B1 (en) Aerosol containing cytokines and use thereof
WO1990004977A3 (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
Mitsuyasu Use of recombinant interferons and hematopoietic growth factors in patients infected with human immunodeficiency virus
Miles Practical Use of Hematopoietic Growth Factors in HIV Infection
WO1990001328A1 (en) Tnf and formulations thereof in the treatment or prophylaxis of hepatitis b
Izzedine et al. Tolerance and pharmacokinetics of high doses of interferon-alpha-2a in a hemodialysis patient
IT1284852B1 (en) Use of natural human alpha-interferon - in preparation of liquid medicaments for peroral administration for treating viral infections, neoplasia and immune diseases
IT1283945B1 (en) Use of natural human alpha-interferon - in preparation of liquid medicaments for peroral administration for treating viral infections, neoplasia and immune diseases
Einhorn et al. Treatment of advanced condylomata acuminata with semi-purified and purified human leukocyte interferon
RU94023600A (en) METHOD FOR TREATING HEMOCHROMATOSIS
CA2199154A1 (en) The use of medicaments containing interferon-beta
HUP9902188A2 (en) Pharmaceutical compositions comprising natural human alfa-interferon
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.
RU2001128509A (en) METHOD FOR TREATING NEURODEGENERATION